<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636684</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/19/0446</org_study_id>
    <nct_id>NCT04636684</nct_id>
  </id_info>
  <brief_title>Prevalence and Significance of ATTR Aortic Valve Amyloidosis in Degenerative Aortic Stenosis</brief_title>
  <acronym>RACAMYL</acronym>
  <official_title>Prevalence and Significance of ATTR Aortic Valve Amyloidosis in Degenerative Aortic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac amyloidosis is a restrictive cardiomyopathy with a potentially severe prognosis that&#xD;
      can be life-threatening. It is linked in the vast majority of cases to a light chain&#xD;
      deposition of immunoglobulin or transthyretin. Although myocardial involvement is&#xD;
      predominant, other locations are possible: the atrioventricular conduction system, coronary&#xD;
      arteries and valve leaflets. In systematic histological analyzes, deposits of amyloidosis&#xD;
      infiltrating the aortic valve have been reported with a frequency of up to 74% for&#xD;
      degenerative RA. The nature of these deposits has never been established because the&#xD;
      immunostaining carried out all remained negative, probably due to decalcification prior to&#xD;
      cutting. Currently, these deposits are considered to be local degenerative phenomena without&#xD;
      clinical repercussions. However, the use of bone scintigraphy has shown a high prevalence,&#xD;
      between 14 and 16%, of ATTR cardiac amyloidosis in patients with severe RA. The diagnosis of&#xD;
      ATTR amyloidosis has been proven histologically in a few patients. Sequencing of the TTR gene&#xD;
      has shown that they are mainly wild forms. In fact, the prevalence of transthyretin mutations&#xD;
      in our local cohort is 20%.&#xD;
&#xD;
      The objective of this study is to determine by proteomic analysis based on mass spectrometry,&#xD;
      the prevalence of ATTR aortic valve amyloidosis in patients undergoing surgical valve&#xD;
      replacement for degenerative aortic stenosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>prevalence rate of valvular ATTR amyloidosis</measure>
    <time_frame>1 year</time_frame>
    <description>calculation of the prevalence rate of valvular ATTR amyloidosis with its 95% confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of ATTR myocardial amyloidosis revealed by bone scintigraphy</measure>
    <time_frame>1 year</time_frame>
    <description>The prevalence of ATTR myocardial amyloidosis revealed by bone scintigraphy (HMDP scan) will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of wild ATTR myocardial amyloidosis</measure>
    <time_frame>1 year</time_frame>
    <description>The percentage of wild ATTR forms will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of mutated ATTR myocardial amyloidosis</measure>
    <time_frame>1 year</time_frame>
    <description>The percentage of mutated ATTR forms will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of types of amyloidosis other than ATTR</measure>
    <time_frame>1 year</time_frame>
    <description>The prevalence of types of amyloidosis other than ATTR will be calculated</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Amyloidosis</condition>
  <arm_group>
    <arm_group_label>patients undergoing surgical valve replacement for degenerative aortic stenosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Proteomic analysis</intervention_name>
    <description>Proteomic analysis based on mass spectrometry on the sample of valve tissues.</description>
    <arm_group_label>patients undergoing surgical valve replacement for degenerative aortic stenosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 18 years old&#xD;
&#xD;
          -  Degenerative aortic stenosis&#xD;
&#xD;
          -  Aortic valve replacement surgery&#xD;
&#xD;
          -  Signature of the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-degenerative aortic stenosis: bicuspid, rheumatic disease, aortic regurgitation&#xD;
&#xD;
          -  Persons under a system of legal protection for adults (guardianship, curatorship,&#xD;
             etc.)&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magali COLOMBAT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magali COLOMBAT, MD</last_name>
    <phone>5 31 15 61 40</phone>
    <phone_ext>+33</phone_ext>
    <email>colomat.m@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivier LAIREZ, MD</last_name>
    <phone>5 61 32 28 73</phone>
    <phone_ext>+33</phone_ext>
    <email>lairez.o@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>university hospital center Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey TOMASIK</last_name>
      <phone>5 61 77 85 97</phone>
      <phone_ext>+33</phone_ext>
      <email>tomasik.a@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>November 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ATTR aortic valve amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

